Education
About Us
Working with TipRanks
Follow Us
Pharvaris (PHVS)
NASDAQ:PHVS
PHVS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$14.14 - $26.99
Previous CloseN/A
Volume14.65K
Average Volume (3M)43.77K
Market Cap
$810.66M
Enterprise Value$660.90M
Total Cash (Recent Filing)€5.08M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta1.64
Next Earnings
Apr 24, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.68
Shares Outstanding54,007,710
10 Day Avg. Volume59,758
30 Day Avg. Volume43,772
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$34.33Price Target Upside128.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
---
Pharvaris News
PremiumCompany Announcements
Pharvaris Sets 2025 Strategic Priorities in HAE and AAE Treatments
PremiumCompany Announcements
Pharvaris Reports Q3 2024 Progress and Financials
PremiumCompany Announcements
Pharvaris Advances in HAE Treatment with Strong Financials
---
Bulls Say, Bears Say
Bulls Say
Market PotentialPharvaris' oral deucrictibant has promising efficacy and safety in hereditary angioedema (HAE), both as an on-demand therapy for acute attacks and in long-term prophylactic settings.
Product EfficacyDeucrictibant has promising efficacy as a long-term prophylactic therapy, showing significant attack reduction in trials.
Bears Say
Market CompetitionDespite the entrenched competition in HAE, deucrictibant's differentiated profile could drive blockbuster sales.
---
Ownership Overview
―
Insiders
7.40% Mutual Funds
68.91% Other Institutional Investors
23.37% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
PHVS FAQ
What was Pharvaris’s price range in the past 12 months?
Pharvaris lowest stock price was $14.14 and its highest was $26.99 in the past 12 months.
What is Pharvaris’s market cap?
Pharvaris’s market cap is $810.66M.
When is Pharvaris’s upcoming earnings report date?
Pharvaris’s upcoming earnings report date is Apr 24, 2025 which is in 45 days.
How were Pharvaris’s earnings last quarter?
Pharvaris released its earnings results on Nov 13, 2024. The company reported -$0.833 earnings per share for the quarter, missing the consensus estimate of -$0.64 by -$0.193.
Is Pharvaris overvalued?
According to Wall Street analysts Pharvaris’s price is currently Undervalued.
Does Pharvaris pay dividends?
Pharvaris does not currently pay dividends.
What is Pharvaris’s EPS estimate?
Pharvaris’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pharvaris have?
Pharvaris has 54,007,710 shares outstanding.
What happened to Pharvaris’s price movement after its last earnings report?
Pharvaris reported an EPS of -$0.833 in its last earnings report, missing expectations of -$0.64. Following the earnings report the stock price went up 2.545%.
Which hedge fund is a major shareholder of Pharvaris?
Currently, no hedge funds are holding shares in PHVS
---
Pharvaris Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$34.33 (128.71% Upside)
$34.33 (128.71% Upside)
Hedge Fund Trend
Increased
By 30.3K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.07%
12-Months-Change
Fundamentals
Return on Equity
-58.16%
Trailing 12-Months
Asset Growth
94.95%
Trailing 12-Months
Company Description
Pharvaris
Pharvaris NV is a clinical-stage company. It is focused on the discovery and development of novel oral bradykinin B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications.
---
PHVS Stock 12 Month Forecast
Average Price Target
$34.33
▲(128.71% Upside)
Technical Analysis
Eloxx Pharmaceuticals
―
AnaptysBio
―
Kiniksa Pharmaceuticals
―
Akero Therapeutics
―
Arcutis Biotherapeutics
―
Best Analysts Covering PHVS
1 Year
1 Year Success Rate
10/24 ratings generated profit
1 Year Average Return
+45.50%
reiterated a buy rating 7 days ago
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 41.67% of your transactions generating a profit, with an average return of +45.50% per trade.
---